This study, "Stranger than Family: Decision-Making & Ethics of Substitution for People Living With
Dementia Going It Alone", explores how people facing dementia alone are connected with a substitute
decision-maker and how ideas about capacity, consent, and decision-making affect them.
Interviews will be conducted with:
- People who are facing dementia alone
- Healthcare and social service workers
- Substitute decision-makers for others who are not close family members or close friends
The overall goal of this study is to identify opportunities for advocacy, policy, and practice change to
better support people facing dementia alone.
You are eligible to participate if you:
- Live in Ontario or Alberta AND
- Have a diagnosis of dementia or are at-risk and planning for a future living with dementia and are
facing dementia alone OR
- Are a healthcare or social service worker, or other professional who has experience trying to connect
adult clients with a substitute decision-maker OR
- Have experience as a substitute decision-maker for someone living with dementia who is not a close
family member or friend
In addition, to be eligible you must:
- Be able to participate in an interview over the phone, on Zoom, or in-person AND
- Understand the purpose of the study and what participation involves
[email protected] is a 5-week virtual reality at-home intervention with the goal to explore whether virtual reality experiences can enhance communication between persons living with dementia and their care partners. We also aim to explore how a head-mounted VR system, which delivers a fully immersive experience compares to a Tablet-based technology.
The study is aiming to assess whether nutritional intervention with personalized, preselected prebiotics can affect cognitive function in those with Alzheimer’s disease. This study is placebo-controlled, and participants will be randomized to either the placebo or prebiotic.
We want to determine if a nutrition questionnaire (SCREEN) works well to identify nutrition challenges for older adults with diagnosed memory problems, cognitive impairment or dementia when completed by themselves, or by a care partner on behalf of their cared for person.
You may be eligible if you are:
• 55 years or older
• Read/speak English
• Live within 45km of Waterloo, Guelph or London.
AND are an:
• Older adult with diagnosed memory problems, cognitive impairment or dementia with a care partner who either lives with you, or who is in daily contact with you and would be able to support reporting of their eating behaviours
• If living in a retirement home, the older adult must have lived in their home for at least 3 months and receive 2 or more meals each day from their retirement home
The purpose of this study is to understand what supports and prevents people living with dementia from participating in physical activity during the winter months. Identifying what helps or hinders winter physical activity can help inform researchers to create exercise interventions that are seasonally appropriate to persons with dementia. It can also allow policy makers to target key areas of improvement, such as icy sidewalks, to better support winter physical activity.
All participants must:
• Live in the community
• Be able to speak and understand English
• Be able to access and use Zoom using a computer or tablet
• Live in a region in Canada that regularly experiences snow or ice during the winter months.
Persons with dementia must:
• Be above the age of 55
• Be able to read and understand the consent process
• Be able to understand the nature of the interview
Care partners must:
• Identify as a primary family care partner for a person with dementia or mild cognitive impairment
• Not identify as someone living with dementia
This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease.
50 years or older, with mild to moderate Alzheimer’s Disease
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.